Showing 151–175 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Hameed HMA, Islam MM, Chhotaray C, Wang C, Liu Y, et al.
Tuberculosis (TB) is a formidable infectious disease that remains a major cause of death worldwide today. Escalating application of genomic techniques has expedited the identification of increasing number of mutations associated with drug resistance in Mycobacterium tuberculosis …
Singh DK, Bhaskar A, Pahuja I, Shaji A, Moitra B, et al.
Mycobacterium tuberculosis, the causative agent of tuberculosis, is acquiring drug resistance at a faster rate than the discovery of new antibiotics. Therefore, alternate therapies that can limit the drug resistance and disease recurrence are urgently needed. Emerging evidence in…
Katale BZ, Rofael S, Elton L, Mbugi EV, Mpagama SG, et al.
… (WGS)-based prediction of drug resistance in Mycobacterium tuberculosis has the potential to guide clinical decisions in the design of optimal treatment regimens. Methods We utilized WGS to investigate drug resistance mutations in a 32-year-old Tanzanian male admitted to Kibong'…
Khalil ZG, Hill TA, De Leon Rodriguez LM, Lohman RJ, Hoang HN, et al.
…r in vitro growth-inhibitory activity against Mycobacterium tuberculosis (H37Rv, H37Ra, CDC1551, HN878, and HN353). The most potent antimycobacterial wollamides were those where residue VI d-Orn (wollamide B) was replaced by d-Arg (wollamide B1) or d-Lys (wollamide B2), with all …
Rens C, Chao JD, Sexton DL, Tocheva EI, Av-Gay Y
The success of Mycobacterium tuberculosis as a pathogen is well established: tuberculosis is the leading cause of death by a single infectious agent worldwide. The threat of multi- and extensively drug-resistant bacteria has renewed global concerns about this pathogen and underst…
Quach D, Sharp M, Ahmed S, Ames L, Bhagwat A, et al.
Tuberculosis (TB), caused by Mycobacterium tuberculosis , remains a significant global health threat, affecting an estimated 10.6 million people in 2022. The emergence of multidrug resistant and extensively drug resistant strains necessitates the development of novel and effectiv…
Morey-León G, Mejía-Ponce PM, Granda Pardo JC, Muñoz-Mawyin K, Fernández-Cadena JC, et al.
Introduction Tuberculosis (TB) is among the deadliest diseases worldwide, and its impact is mainly due to the continuous emergence of resistant isolates during treatment due to the laborious process of resistance diagnosis, nonadherence to treatment and circulation of previously …
Baldin VP, Scodro RBL, Lopes-Ortiz MA, de Almeida AL, Gazim ZC, et al.
Background The global resurgence of tuberculosis (TB) and the development of drug resistance, as multidrug-resistant (MDR) and extensively drug-resistant (XDR) Mycobacterium tuberculosis isolates, are a threat to TB control and have created a need for new and more effective anti-…
Guo H, Courbon GM, Bueler SA, Mai J, Liu J, et al.
Tuberculosis-the world's leading cause of death by infectious disease-is increasingly resistant to current first-line antibiotics 1 . The bacterium Mycobacterium tuberculosis (which causes tuberculosis) can survive low-energy conditions, allowing infections to remain dormant and …
Islam MM, Tan Y, Hameed HMA, Liu Y, Chhotaray C, et al.
Objectives Amikacin is the only second-line injectable antituberculosis (anti-TB) drug still recommended for multidrug-resistant tuberculosis (MDR-TB) treatment when a short MDR-TB regimen is designed. Mutations in rrs and eis are reported to be associated with resistance to amik…
Onajole OK, Lun S, Yun YJ, Langue DY, Jaskula-Dybka M, et al.
Tuberculosis (TB) is a highly infectious disease that has been plaguing the human race for centuries. The emergence of multidrug-resistant strains of TB has been detrimental to the fight against tuberculosis with very few safe therapeutic options available. As part of an ongoing …
Silva S, Santos-Silva A, da Costa JMC, Vale N
Background Tuberculosis (TB) is known to be one of the 10 causes of global death by infectious agents. The increasing numbers of multiple antibiotic resistance (MDR-TB) and cases of extensive resistance to antibiotics (XDR-TB) have led to the development of new and effective TB t…
Guo Y, Yang J, Wang W, Wu X, Wan B, et al.
Background New antituberculosis drugs have recently been approved for the treatment of multidrug-resistant tuberculosis TB (MDR-TB). We aimed to describe the distributions of bedaquiline, delamanid, linezolid, clofazimine, and capreomycin MIC values for M. tuberculosis . Methods …
Xiang W, He H, Duan X, He Z, Xu X, et al.
Importance Drug therapy remains the cornerstone of tuberculosis (TB) treatment, yet first-line anti-tuberculosis drugs are associated with significant adverse effects that can compromise patient outcomes. Moreover, prolonged and widespread use has led to an alarming rise in drug-…
Dokladda K, Billamas P, Jaitrong S, Suwanakitti N, Phornsiricharoenphant W, et al.
…id (PAS) was first reported by Lehmann in 1946 and used for tuberculosis treatment. However, due to its adverse effects, it is now used only as a second line anti-tuberculosis drug for treatment of multidrug resistant or extensively drug resistant M. tuberculosis. The structure o…
Mourenza Á, Gil JA, Mateos LM, Letek M
Tuberculosis is the leading cause of death, worldwide, due to a bacterial pathogen. This respiratory disease is caused by the intracellular pathogen Mycobacterium tuberculosis and produces 1.5 million deaths every year. The incidence of tuberculosis has decreased during the last …
Yadav S
Drug-resistant tuberculosis is a noteworthy threat to public health, especially in high-burden countries. Management of these types of tuberculosis is lengthy and associated with a number of adverse drug reactions. Pre-extensively drug-resistant tuberculosis is a serious type of …
Intorasoot S, Intorasoot A, Tawteamwong A, Butr-Indr B, Phunpae P, et al.
Tuberculosis is a highly contagious disease caused by the Mycobacterium tuberculosis complex (MTBC). Although TB is treatable, multidrug-resistant, extensively drug-resistant, and totally drug-resistant forms of M. tuberculosis have become a new life-threatening concern. New anti…
Liang S, Xu X, Yang Z, Du Q, Zhou L, et al.
…aracteristics of chest abnormalities between drug-resistant tuberculosis (DR-TB) and drug-sensitive tuberculosis (DS-TB) on chest computed tomography (CT) are of potential value in differential diagnosis, which is challenging in the clinic. Hence, based on 1176 chest CT volumes f…
Nguyen QH, Contamin L, Nguyen TVA, Bañuls AL
…the successful transmission of drug-resistant Mycobacterium tuberculosis , including multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains, in human populations, threatens tuberculosis control worldwide. Differently from many other bacteria, M. tuberculosis drug …
Degiacomi G, Sammartino JC, Sinigiani V, Marra P, Urbani A, et al.
Tuberculosis (TB) is one of the major causes of death related to antimicrobial resistance worldwide because of the spread of Mycobacterium tuberculosis multi- and extensively drug resistant (multi-drug resistant (MDR) and extensively drug-resistant (XDR), respectively) clinical i…
Yang Zhang, Ruiying Wu, Mingrui Sun, Xiaotian Li, Ren Fang, et al.
Tuberculosis, a chronic infectious disease caused bycomplex, has re-emerged as the leading cause of death worldwide as a single infectious agent. The increasing prevalence of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis poses a severe and growing t…
Qureshi H, Shah Z, Raja MAZ, Alshahrani MY, Khan WA, et al.
Tuberculosis (T.B.) remains a prominent global cause of health challenges and death, exacerbated by drug-resistant strains such as multidrug-resistant tuberculosis MDR-TB and extensively drug-resistant tuberculosis XDR-TB. For an effective disease management strategy, it is cruci…
Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, et al.
Background Patients with highly drug-resistant forms of tuberculosis have limited treatment options and historically have had poor outcomes. Methods In an open-label, single-group study in which follow-up is ongoing at three South African sites, we investigated treatment with thr…
Ying Wang, Daxing Cao, Guihua Liu
Treatment regimens for Tuberculosis (TB) primarily rely on first-line drugs such as isoniazid, rifampicin, ethambutol, and pyrazinamide. Although these drugs have been pivotal in the treatment of drug-resistant tuberculosis, their high costs limit widespread use in low- and middl…